Go Pro

Aravive (ARAV) Competitors

Aravive logo
$0.04 0.00 (0.00%)
As of 08/25/2026

ARAV vs. ALVOW, APLMW, BIAFW, BIVIW, and CDIOW

Should you buy Aravive stock or one of its competitors? Aravive's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), bioAffinity Technologies (BIAFW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aravive compare to Alvotech?

Aravive (NASDAQ:ARAV) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Alvotech$491.95MN/AN/AN/AN/A

In the previous week, Alvotech had 5 more articles in the media than Aravive. MarketBeat recorded 5 mentions for Alvotech and 0 mentions for Aravive. Alvotech's average media sentiment score of 0.36 beat Aravive's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Alvotech Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Apollomics?

Aravive (NASDAQ:ARAV) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Apollomics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Aravive. Apollomics' average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Apollomics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Apollomics$8.50MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Apollomics N/A N/A N/A

Summary

Apollomics beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, bioAffinity Technologies had 3 more articles in the media than Aravive. MarketBeat recorded 3 mentions for bioAffinity Technologies and 0 mentions for Aravive. bioAffinity Technologies' average media sentiment score of 0.30 beat Aravive's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Neutral
Aravive Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Summary

bioAffinity Technologies beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to BioVie?

BioVie (NASDAQ:BIVIW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BioVie had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Aravive. BioVie's average media sentiment score of 0.43 beat Aravive's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Neutral
Aravive Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Aravive N/A N/A N/A

Summary

BioVie and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Aravive compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$14.45KN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Cardio Diagnostics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Cardio Diagnostics and 0 mentions for Aravive. Cardio Diagnostics' average media sentiment score of 0.44 beat Aravive's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Cardio Diagnostics Neutral
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
Aravive N/A N/A N/A

Summary

Cardio Diagnostics beats Aravive on 3 of the 5 factors compared between the two stocks.

Get Aravive News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARAV vs. The Competition

MetricAraviveBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.03B$7.29B$12.77B
Dividend YieldN/A3.63%2.54%10.79%
P/E Ratio-0.0411.48272.7624.14
Price / SalesN/A1,366.69626.7298.11
Price / CashN/A103.6478.5753.12
Price / BookN/A16.8813.146.23
Net IncomeN/A-$22.76M$3.47B$348.07M
7 Day PerformanceN/A1.55%1.38%0.67%
1 Month PerformanceN/A11.70%8.62%4.84%
1 Year PerformanceN/A56.88%25.90%16.83%

Aravive Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARAV
Aravive
N/A$0.04
flat
N/AN/A$0.00N/AN/A20
ALVOW
Alvotech
N/A$0.20
-7.2%
N/A-58.0%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
-1.9%
N/A-32.6%$0.00$8.50MN/A59
BIAFW
bioAffinity Technologies
N/A$0.12
+37.7%
N/A+90.0%$0.00$5.85MN/A10
BIVIW
BioVie
N/A$0.25
+55.4%
N/AN/A$0.00N/AN/AN/A

Related Companies and Tools


This page (NASDAQ:ARAV) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners